Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma
have increased the complexity of patient management. A dynamic adaptation of the …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice
are becoming increasingly related to sustained virological response after hepatitis C …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the
sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient …

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Recent advances in systemic and locoregional treatments for patients with unresectable or
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …